Which has stronger earnings & valuation, ALLO or NBP?

I-Mab has higher revenue and earnings than Allogene Therapeutics. I-Mab is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Allogene Therapeutics $20K 35,377.88 -$190.89M -$0.77 N/A I-Mab $3.89M 47.57 -$46.27M -$0.36 N/A

Is ALLO or NBP more profitable?

I-Mab's return on equity of 0.00% beat Allogene Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Allogene Therapeutics N/A -56.45% -40.36% I-Mab N/A N/A N/A

Which has preferable valuation & earnings, NBP or CRMD?

CorMedix has higher revenue and earnings than I-Mab. I-Mab is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio I-Mab $3.89M 47.57 -$46.27M -$0.36 N/A CorMedix $311.71M 2.11 $163.05M $2.13 3.94

Is NBP or CRMD more profitable?

CorMedix has a net margin of 45.25% compared to I-Mab's net margin of 0.00%. CorMedix's return on equity of 45.57% beat I-Mab's return on equity. Company Net Margins Return on Equity Return on Assets I-Mab N/A N/A N/A CorMedix 45.25% 45.57% 24.76%

Which has higher valuation and earnings, CLYM or NBP?

I-Mab has higher revenue and earnings than Climb Bio. Climb Bio is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Climb Bio N/A N/A -$59.85M -$0.78 N/A I-Mab $3.89M 47.57 -$46.27M -$0.36 N/A

Is CLYM or NBP more profitable?

I-Mab's return on equity of 0.00% beat Climb Bio's return on equity. Company Net Margins Return on Equity Return on Assets Climb Bio N/A -31.45% -30.39% I-Mab N/A N/A N/A

Is AURA or NBP more profitable?

I-Mab's return on equity of 0.00% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Aura Biosciences N/A -78.12% -64.08% I-Mab N/A N/A N/A

Which has preferable valuation and earnings, OCS or NBP?

I-Mab has higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oculis $1.45M 462.24 -$119.44M -$2.13 N/A I-Mab $3.89M 47.57 -$46.27M -$0.36 N/A

Is OCS or NBP more profitable?

I-Mab has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. I-Mab's return on equity of 0.00% beat Oculis' return on equity. Company Net Margins Return on Equity Return on Assets Oculis -8,460.67% -56.78% -45.62% I-Mab N/A N/A N/A

I-Mab (NBP) Competitors

$1.60 -0.01 (-0.62%)

Closing price 06/24/2026 04:00 PM Eastern

Extended Trading

$1.62 +0.02 (+1.25%)

As of 06/24/2026 07:10 PM Eastern

Compare

NBP vs. ALLO, CRMD, CLYM, AURA, and OCS

Should you buy I-Mab stock or one of its competitors? MarketBeat compares I-Mab with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with I-Mab include Allogene Therapeutics (ALLO), CorMedix (CRMD), Climb Bio (CLYM), Aura Biosciences (AURA), and Oculis (OCS). These companies are all part of the "pharmaceutical products" industry.

How does I-Mab compare to Allogene Therapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and I-Mab (NASDAQ:NBP) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Allogene Therapeutics currently has a consensus target price of $8.52, indicating a potential upside of 315.72%. I-Mab has a consensus target price of $9.00, indicating a potential upside of 462.50%. Given I-Mab's higher probable upside, analysts plainly believe I-Mab is more favorable than Allogene Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 38.4% of I-Mab shares are held by institutional investors. 13.2% of Allogene Therapeutics shares are held by insiders. Comparatively, 22.1% of I-Mab shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, I-Mab had 1 more articles in the media than Allogene Therapeutics. MarketBeat recorded 1 mentions for I-Mab and 0 mentions for Allogene Therapeutics. I-Mab's average media sentiment score of -1.00 beat Allogene Therapeutics' score of -1.74 indicating that I-Mab is being referred to more favorably in the news media.

Company	Overall Sentiment
Allogene Therapeutics	Very Negative
I-Mab	Negative

I-Mab's return on equity of 0.00% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-56.45%	-40.36%
I-Mab	N/A	N/A	N/A

I-Mab has higher revenue and earnings than Allogene Therapeutics. I-Mab is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	35,377.88	-$190.89M	-$0.77	N/A
I-Mab	$3.89M	47.57	-$46.27M	-$0.36	N/A

Allogene Therapeutics has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market. Comparatively, I-Mab has a beta of 1.47, suggesting that its share price is 47% more volatile than the broader market.

Summary

I-Mab beats Allogene Therapeutics on 10 of the 16 factors compared between the two stocks.

How does I-Mab compare to CorMedix?

I-Mab (NASDAQ:NBP) and CorMedix (NASDAQ:CRMD) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

In the previous week, CorMedix had 1 more articles in the media than I-Mab. MarketBeat recorded 2 mentions for CorMedix and 1 mentions for I-Mab. CorMedix's average media sentiment score of 0.34 beat I-Mab's score of -1.00 indicating that CorMedix is being referred to more favorably in the news media.

Company	Overall Sentiment
I-Mab	Negative
CorMedix	Neutral

I-Mab has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market. Comparatively, CorMedix has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market.

38.4% of I-Mab shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 22.1% of I-Mab shares are owned by insiders. Comparatively, 3.5% of CorMedix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

I-Mab presently has a consensus price target of $9.00, suggesting a potential upside of 462.50%. CorMedix has a consensus price target of $15.00, suggesting a potential upside of 78.78%. Given I-Mab's higher possible upside, equities research analysts clearly believe I-Mab is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

CorMedix has a net margin of 45.25% compared to I-Mab's net margin of 0.00%. CorMedix's return on equity of 45.57% beat I-Mab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
CorMedix	45.25%	45.57%	24.76%

CorMedix has higher revenue and earnings than I-Mab. I-Mab is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$3.89M	47.57	-$46.27M	-$0.36	N/A
CorMedix	$311.71M	2.11	$163.05M	$2.13	3.94

Summary

CorMedix beats I-Mab on 11 of the 16 factors compared between the two stocks.

How does I-Mab compare to Climb Bio?

Climb Bio (NASDAQ:CLYM) and I-Mab (NASDAQ:NBP) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

Climb Bio has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market. Comparatively, I-Mab has a beta of 1.47, meaning that its share price is 47% more volatile than the broader market.

69.8% of Climb Bio shares are held by institutional investors. Comparatively, 38.4% of I-Mab shares are held by institutional investors. 2.6% of Climb Bio shares are held by insiders. Comparatively, 22.1% of I-Mab shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

I-Mab has higher revenue and earnings than Climb Bio. Climb Bio is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A
I-Mab	$3.89M	47.57	-$46.27M	-$0.36	N/A

In the previous week, Climb Bio had 1 more articles in the media than I-Mab. MarketBeat recorded 2 mentions for Climb Bio and 1 mentions for I-Mab. Climb Bio's average media sentiment score of 0.00 beat I-Mab's score of -1.00 indicating that Climb Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Climb Bio	Neutral
I-Mab	Negative

I-Mab's return on equity of 0.00% beat Climb Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-31.45%	-30.39%
I-Mab	N/A	N/A	N/A

Climb Bio presently has a consensus target price of $21.73, suggesting a potential upside of 70.41%. I-Mab has a consensus target price of $9.00, suggesting a potential upside of 462.50%. Given I-Mab's higher probable upside, analysts clearly believe I-Mab is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

I-Mab beats Climb Bio on 9 of the 15 factors compared between the two stocks.

How does I-Mab compare to Aura Biosciences?

Aura Biosciences (NASDAQ:AURA) and I-Mab (NASDAQ:NBP) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

I-Mab's return on equity of 0.00% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-78.12%	-64.08%
I-Mab	N/A	N/A	N/A

I-Mab has higher revenue and earnings than Aura Biosciences. I-Mab is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A
I-Mab	$3.89M	47.57	-$46.27M	-$0.36	N/A

Aura Biosciences currently has a consensus target price of $20.50, indicating a potential upside of 191.19%. I-Mab has a consensus target price of $9.00, indicating a potential upside of 462.50%. Given I-Mab's higher possible upside, analysts clearly believe I-Mab is more favorable than Aura Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

96.8% of Aura Biosciences shares are owned by institutional investors. Comparatively, 38.4% of I-Mab shares are owned by institutional investors. 6.3% of Aura Biosciences shares are owned by insiders. Comparatively, 22.1% of I-Mab shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, I-Mab had 1 more articles in the media than Aura Biosciences. MarketBeat recorded 1 mentions for I-Mab and 0 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 0.94 beat I-Mab's score of -1.00 indicating that Aura Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Aura Biosciences	Positive
I-Mab	Negative

Aura Biosciences has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market. Comparatively, I-Mab has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market.

Summary

I-Mab beats Aura Biosciences on 9 of the 14 factors compared between the two stocks.

How does I-Mab compare to Oculis?

Oculis (NASDAQ:OCS) and I-Mab (NASDAQ:NBP) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

Oculis presently has a consensus target price of $38.33, suggesting a potential upside of 231.60%. I-Mab has a consensus target price of $9.00, suggesting a potential upside of 462.50%. Given I-Mab's higher possible upside, analysts plainly believe I-Mab is more favorable than Oculis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

22.3% of Oculis shares are held by institutional investors. Comparatively, 38.4% of I-Mab shares are held by institutional investors. 22.1% of I-Mab shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Oculis had 1 more articles in the media than I-Mab. MarketBeat recorded 2 mentions for Oculis and 1 mentions for I-Mab. Oculis' average media sentiment score of 0.00 beat I-Mab's score of -1.00 indicating that Oculis is being referred to more favorably in the media.

Company	Overall Sentiment
Oculis	Neutral
I-Mab	Negative

I-Mab has higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$1.45M	462.24	-$119.44M	-$2.13	N/A
I-Mab	$3.89M	47.57	-$46.27M	-$0.36	N/A

Oculis has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market. Comparatively, I-Mab has a beta of 1.47, indicating that its stock price is 47% more volatile than the broader market.

I-Mab has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. I-Mab's return on equity of 0.00% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-8,460.67%	-56.78%	-45.62%
I-Mab	N/A	N/A	N/A

Summary

I-Mab beats Oculis on 11 of the 16 factors compared between the two stocks.

Get I-Mab News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NBP vs. The Competition

Export

Metric	I-Mab	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$186.19M	$2.93B	$5.00B	$12.32B
Dividend Yield	N/A	15.20%	11.45%	5.88%
P/E Ratio	-4.44	13.52	22.00	23.96
Price / Sales	47.57	3,019.13	155.03	107.90
Price / Cash	N/A	26.47	39.06	53.76
Price / Book	0.80	4.79	15.93	6.41
Net Income	-$46.27M	-$34.85M	$115.37M	$337.14M
7 Day Performance	6.67%	-1.29%	-1.69%	-1.06%
1 Month Performance	-9.60%	-1.12%	-2.46%	0.49%
1 Year Performance	N/A	13.76%	11.43%	28.43%

I-Mab Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NBP I-Mab	3.4083 of 5 stars	$1.60 -0.6%	$9.00 +462.5%	N/A	$186.19M	$3.89M	N/A	380	Positive News
ALLO Allogene Therapeutics	2.3484 of 5 stars	$2.00 flat	$8.52 +326.1%	+64.0%	$690.31M	$20K	N/A	310	Negative News High Trading Volume
CRMD CorMedix	3.4498 of 5 stars	$8.67 flat	$15.00 +73.0%	-46.6%	$680.18M	$311.71M	4.59	30	High Trading Volume
CLYM Climb Bio	3.1914 of 5 stars	$11.45 flat	$21.73 +89.8%	+888.4%	$655.66M	N/A	N/A	9	Analyst Forecast
AURA Aura Biosciences	2.9211 of 5 stars	$6.34 flat	$20.50 +223.3%	+7.5%	$655.47M	N/A	N/A	50	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NBP) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

I-Mab (NBP) Competitors

NBP vs. ALLO, CRMD, CLYM, AURA, and OCS

How does I-Mab compare to Allogene Therapeutics?

Summary

How does I-Mab compare to CorMedix?

Summary

How does I-Mab compare to Climb Bio?

Summary

How does I-Mab compare to Aura Biosciences?

Summary

How does I-Mab compare to Oculis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBP vs. The Competition

I-Mab Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

I-Mab (NBP) Competitors

NBP vs. ALLO, CRMD, CLYM, AURA, and OCS

How does I-Mab compare to Allogene Therapeutics?

Do analysts recommend ALLO or NBP?

Do institutionals and insiders believe in ALLO or NBP?

Does the media refer more to ALLO or NBP?

Is ALLO or NBP more profitable?

Which has stronger earnings & valuation, ALLO or NBP?

Which has more risk and volatility, ALLO or NBP?

Summary

How does I-Mab compare to CorMedix?

Does the media prefer NBP or CRMD?

Which has more risk & volatility, NBP or CRMD?

Do insiders & institutionals hold more shares of NBP or CRMD?

Do analysts prefer NBP or CRMD?

Is NBP or CRMD more profitable?

Which has preferable valuation & earnings, NBP or CRMD?

Summary

How does I-Mab compare to Climb Bio?

Which has more volatility & risk, CLYM or NBP?

Do institutionals and insiders believe in CLYM or NBP?

Which has higher valuation and earnings, CLYM or NBP?

Does the media refer more to CLYM or NBP?

Is CLYM or NBP more profitable?

Do analysts prefer CLYM or NBP?

Summary

How does I-Mab compare to Aura Biosciences?

Is AURA or NBP more profitable?

Which has higher valuation and earnings, AURA or NBP?

Do analysts rate AURA or NBP?

Do insiders and institutionals have more ownership in AURA or NBP?

Does the media favor AURA or NBP?

Which has more risk & volatility, AURA or NBP?

Summary

How does I-Mab compare to Oculis?

Do analysts rate OCS or NBP?

Do insiders & institutionals believe in OCS or NBP?

Does the media favor OCS or NBP?

Which has preferable valuation and earnings, OCS or NBP?

Which has more risk and volatility, OCS or NBP?

Is OCS or NBP more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBP vs. The Competition

I-Mab Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools